• Je něco špatně v tomto záznamu ?

Tadalafil v léčbě plicní arteriální hypertenze
[Tadalafil therapy for pulmonary arterial hypertension]

Galie N., et al.

. 2009 ; 3 (6) : 47-48.

Jazyk čeština Země Česko

Perzistentní odkaz   https://www.medvik.cz/link/bmc10004446

Treatment options for pulmonary arterial hypertension target the prostacyclin, endothelin, or nitric oxide pathways. Tadalafil, a phosphodiesterase type-5 inhibitor, increases cGMP, the final mediator in the nitric oxide pathway. METHODS AND RESULTS: In this 16-week, double-blind, placebo-controlled study, 405 patients with pulmonary arterial hypertension (idiopathic or associated), either treatment-naive or on background therapy with the endothelin receptor antagonist bosentan, were randomized to placebo or tadalafil 2.5, 10, 20, or 40 mg orally once daily. The primary end point was the change from baseline to week 16 in the distance walked in 6 minutes. Changes in World Health Organization functional class, clinical worsening, and health-related quality of life were also assessed. Patients completing the 16-week study could enter a long-term extension study. Tadalafil increased the distance walked in 6 minutes in a dose-dependent manner; only the 40-mg dose met the prespecified level of statistical significance (P<0.01). Overall, the mean placebo-corrected treatment effect was 33 m (95% confidence interval, 15 to 50 m). In the bosentan-naive group, the treatment effect was 44 m (95% confidence interval, 20 to 69 m) compared with 23 m (95% confidence interval, -2 to 48 m) in patients on background bosentan therapy. Tadalafil 40 mg improved the time to clinical worsening (P=0.041), incidence of clinical worsening (68% relative risk reduction; P=0.038), and health-related quality of life. The changes in World Health Organization functional class were not statistically significant. The most common treatment-related adverse events reported with tadalafil were headache, myalgia, and flushing. CONCLUSIONS: In patients with pulmonary arterial hypertension, tadalafil 40 mg was well tolerated and improved exercise capacity and quality of life measures and reduced clinical worsening.

Tadalafil therapy for pulmonary arterial hypertension

Recenze v:

Komentář [k článku Tadalafil v léčbě plicní arteriální hypertenze].

000      
00000naa 2200000 a 4500
001      
bmc10004446
003      
CZ-PrNML
005      
20111210160441.0
008      
100222s2009 xr e cze||
009      
AR
040    __
$a ABA008 $b cze $c ABA008 $d ABA008 $e AACR2
041    0_
$a cze $b eng
044    __
$a xr
100    1_
$a Galie, N.
245    10
$a Tadalafil v léčbě plicní arteriální hypertenze / $c Galie N., et al.
246    11
$a Tadalafil therapy for pulmonary arterial hypertension
314    __
$a Institute of Cardiology, University of Bologna, Bologna
520    9_
$a Treatment options for pulmonary arterial hypertension target the prostacyclin, endothelin, or nitric oxide pathways. Tadalafil, a phosphodiesterase type-5 inhibitor, increases cGMP, the final mediator in the nitric oxide pathway. METHODS AND RESULTS: In this 16-week, double-blind, placebo-controlled study, 405 patients with pulmonary arterial hypertension (idiopathic or associated), either treatment-naive or on background therapy with the endothelin receptor antagonist bosentan, were randomized to placebo or tadalafil 2.5, 10, 20, or 40 mg orally once daily. The primary end point was the change from baseline to week 16 in the distance walked in 6 minutes. Changes in World Health Organization functional class, clinical worsening, and health-related quality of life were also assessed. Patients completing the 16-week study could enter a long-term extension study. Tadalafil increased the distance walked in 6 minutes in a dose-dependent manner; only the 40-mg dose met the prespecified level of statistical significance (P<0.01). Overall, the mean placebo-corrected treatment effect was 33 m (95% confidence interval, 15 to 50 m). In the bosentan-naive group, the treatment effect was 44 m (95% confidence interval, 20 to 69 m) compared with 23 m (95% confidence interval, -2 to 48 m) in patients on background bosentan therapy. Tadalafil 40 mg improved the time to clinical worsening (P=0.041), incidence of clinical worsening (68% relative risk reduction; P=0.038), and health-related quality of life. The changes in World Health Organization functional class were not statistically significant. The most common treatment-related adverse events reported with tadalafil were headache, myalgia, and flushing. CONCLUSIONS: In patients with pulmonary arterial hypertension, tadalafil 40 mg was well tolerated and improved exercise capacity and quality of life measures and reduced clinical worsening.
650    _2
$a randomizované kontrolované studie jako téma $7 D016032
650    _2
$a financování organizované $7 D005381
650    _2
$a plicní hypertenze $x farmakoterapie $7 D006976
650    _2
$a lidé $7 D006801
773    0_
$w MED00012706 $t Clinical cardiology alert $g Roč. 3, č. 6 (2009), s. 47-48 $x 1213-2586
787    18
$w bmc10004447 $i Recenze v: $t Komentář [k článku Tadalafil v léčbě plicní arteriální hypertenze]
910    __
$a ABA008 $b B 2242 $c 407 a $y 8
990    __
$a 20100222144357 $b ABA008
991    __
$a 20110223105434 $b ABA008
999    __
$a ok $b bmc $g 713867 $s 576815
BAS    __
$a 3
BMC    __
$a 2009 $b 3 $c 6 $d 47-48 $i 1213-2586 $m Clinical Cardiology Alert $x MED00012706
LZP    __
$a 2010-03/mkme

Najít záznam

Citační ukazatele

Možnosti archivace